Management of QT Interval Prolongation in Patients on Antipsychotic Medication

Assessment and Risk Stratification

A QT interval of 459 ms is in the "grey zone" (440-470 ms) which represents an overlap between normal and potentially concerning values, with normal upper QTc values being 450 ms in men and 460 ms in women, according to the European Heart Journal 1
Antipsychotic medications increase the risk of ventricular arrhythmias and sudden cardiac death by 1.53-fold (95% CI 1.38, 1.70), as reported in the European Heart Journal 2, 3
Female gender is a risk factor that increases vulnerability to QT-related arrhythmias, as noted in the European Heart Journal 1
Electrolyte abnormalities, particularly hypokalemia and hypomagnesemia, are risk factors for QT-related arrhythmias, according to the European Heart Journal 1, 2

The European Heart Journal recommends checking if the QTc has increased by >60 ms from baseline, which would warrant dose reduction or discontinuation of the antipsychotic 2, 4
The European Heart Journal suggests monitoring plasma potassium levels and correcting any hypokalemia or hypomagnesemia immediately 2, 5
The American College of Cardiology recommends performing follow-up ECG monitoring to track QTc changes, especially during dose titration, and using Fridericia's formula (QTcF = QT/∛RR) for heart rate correction 1, 7

Different antipsychotics have varying degrees of QT prolongation risk, with thioridazine being high risk, haloperidol and quetiapine being moderate risk, and aripiprazole and olanzapine being low risk, as reported in Praxis Medical Insights: Practical Summaries of Clinical Guidelines 6
The European Heart Journal recommends consulting cardiology if QTc exceeds 500 ms, or if the patient develops cardiac symptoms while on antipsychotic therapy, or if the patient has underlying structural heart disease 1, 2, 4